New Spark Therapeutics (NASDAQ:ONCE)’s Coverage By B. Riley FBR with $74 Target.

June 29, 2018 - By Bridget Boland

Spark Therapeutics, Inc. (NASDAQ:ONCE) Corporate Logo

During 2018 Q1 the big money sentiment decreased to 1.19. That’s change of 0.24, from 2017Q4’s 1.43. 21 investors sold all, 42 reduced holdings as Spark Therapeutics, Inc. ratio turned negative. 42 grew stakes while 33 funds bought stakes. Funds hold 36.74 million shares thus 2.75% more from 2017Q4’s 35.76 million shares.

Fred Alger Mngmt stated it has 0.01% in Spark Therapeutics, Inc. (NASDAQ:ONCE). New York State Common Retirement Fund accumulated 0% or 52,787 shs. Ameriprise Fin holds 0.01% or 168,028 shs. The California-based Capital Ww Investors has invested 0.01% in Spark Therapeutics, Inc. (NASDAQ:ONCE). Point72 Asset Management Limited Partnership reported 38,500 shs. Philadelphia Tru holds 5,800 shs. Teacher Retirement Of Texas holds 6,962 shs. Pinnacle Associates holds 0.31% or 234,430 shs. Td Asset Management Incorporated holds 0.01% or 81,766 shs. Rhumbline Advisers owns 25,959 shs. State Street reported 1.78 million shs. Morgan Stanley has invested 0.01% in Spark Therapeutics, Inc. (NASDAQ:ONCE). Balyasny Asset Mngmt Lc holds 0.01% or 30,424 shs. Bailard owns 0.32% invested in Spark Therapeutics, Inc. (NASDAQ:ONCE) for 75,711 shs. C Gru Hldgs A S reported 0.04% in Spark Therapeutics, Inc. (NASDAQ:ONCE).

What Price Target Has B. Riley FBR Given Spark Therapeutics (NASDAQ:ONCE)

Coverage of Spark Therapeutics (NASDAQ:ONCE)‘s stock has begun on 28 June. B. Riley FBR has $74 target price per share and issued “Neutral” rating which indicates -11.66 % downside potential on ONCE stock.

Spark Therapeutics, Inc. (NASDAQ:ONCE) Ratings Coverage

In total 17 analysts cover Spark Therapeutics (NASDAQ:ONCE). “Buy” rating has 10, “Sell” are 1, while 6 are “Hold”. (NASDAQ:ONCE) has 59% bullish analysts. 30 are the (NASDAQ:ONCE)’s ratings reports on Jun 29, 2018 according to StockzIntelligence Inc. On Tuesday, January 16 Wedbush downgraded Spark Therapeutics, Inc. (NASDAQ:ONCE) to “Underperform” rating. On Wednesday, February 21 the stock has “Buy” rating by Bernstein. The stock rating was maintained by BMO Capital Markets with “Buy” on Tuesday, January 2. On Monday, February 12 the stock of Spark Therapeutics, Inc. (NASDAQ:ONCE) has “Buy” rating given by Mizuho. In Monday, April 30 report Cantor Fitzgerald maintained the stock with “Buy” rating. On Thursday, March 8 the firm has “Outperform” rating by Credit Suisse given. On Wednesday, January 3 the stock of Spark Therapeutics, Inc. (NASDAQ:ONCE) earned “Buy” rating by Cowen & Co. On Wednesday, May 9 Stifel Nicolaus maintained the shares of ONCE in report with “Buy” rating. The stock rating was maintained by BMO Capital Markets with “Buy” on Wednesday, January 24. In Thursday, January 25 report Wedbush maintained the stock with “Sell” rating.

ONCE is touching $83.77 during the last trading session, after increased 1.39%.Spark Therapeutics, Inc. has volume of 92,767 shares. Since June 29, 2017 ONCE has risen 41.78% and is uptrending. ONCE outperformed by 29.21% the S&P 500.

On August, 1 is expected Spark Therapeutics, Inc. (NASDAQ:ONCE)’s earnings report, according to Zacks. Analysts forecast 79.37 % diference or $-0.39 from the $-1.89 EPS from 2017. Last quarter $-1.25 EPS was reported. Analysts sees -68.80 % EPS growth this quarter.

Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases.The firm is valued at $3.13 billion. The Company’s products include LUXTURNA , which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.Currently it has negative earnings. The company's products also comprise SPK-7001 that is in Phase 1/2 trial for choroideremia; SPK-9001, which is in Phase 1/2 trial for hemophilia B; and SPK-8011 that is in Phase 1/2 trial hemophilia A.

For more Spark Therapeutics, Inc. (NASDAQ:ONCE) news published briefly go to: Globenewswire.com, Streetinsider.com, Benzinga.com, Fool.com or Seekingalpha.com. The titles are as follows: “Analysis: Positioning to Benefit within Second Sight Medical Products, ICF International, Morningstar, Spark …” published on June 21, 2018, “B.Riley/FBR Starts Spark Therapeutics (ONCE) at Neutral, ‘AAV Gene Therapy Leader Balances Innovation with Risk'” on June 28, 2018, “Benzinga’s Top Upgrades, Downgrades For June 28, 2018” with a publish date: June 28, 2018, “6 Top Healthcare Trends You Can’t Afford to Ignore” and the last “US IPO Weekly Recap: June Kicks Off To A Slow Start With 2 IPO Pricings But Only One Trading” with publication date: June 09, 2018.

Spark Therapeutics, Inc. (NASDAQ:ONCE) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.